Abbott Laboratories(NYSE:ABT) reported its second-quarter 2025 results on July 17, 2025, posting 7.5% organic sales growth (excluding COVID testing), 12% medical device growth, and adjusted EPS of $1.

Live Updates Live Coverage Updates appear automatically as they are published. Still no earnings at 7:05 a.m. ET 7:04 am by ...

Discover Abbott Laboratories' Q2 2025 highlights: resilience drives high single-digit growth, double-digit EPS, and pipeline innovations.

Abbott, a global healthcare leader, has reported strong results for its second quarter of 2025. According to the company's ...

Elon Musk's dream of having a top-selling electric pickup may be a thing of the past as the Cybertruck continues to see ...

Medical Devices achieved strong double-digit growth, while the Diagnostics segment in China saw ongoing pressure. These 10 stocks could mint the next wave of millionaires › Abbott Laboratories ...

The Motley Fool. DATE Thursday, July 17, 2025 at 9 a.m. ET CALL PARTICIPANTS Chairman and Chief Executive Officer — Robert ...

Abbott (NYSE: ABT) shares dipped before hours today on second-quarter results that came in ahead of the consensus forecast.

General Motors' Hummer EV and Ford's F-150 Lightning beat Tesla's Cybertruck in the US electric pick-up market for Q2 2025.